BACKGROUND: Retinol-binding protein 4 (RBP4) may play an important role in the origin of insulin resistance and metabolic syndrome. Few prospective data are available on the relationship between RBP4 and coronary heart disease (CHD). Furthermore, previous studies did not distinguish among full-length and truncated forms of RBP4 that might have various biological activities. METHODS AND RESULTS: We measured plasma levels of full-length and several C-terminally truncated subfractions of RBP4 among 468 women who developed CHD and 472 matched controls in the Nurses' Health Study cohort during 16 years of follow-up (1990-2006). We observed a temporal variation in the association of full-length RBP4 levels with CHD risk (P=0.04 for testing proportional hazard assumption). In the first 8 years of follow-up, after multivariate adjustment for covariates, the odds ratio of CHD risk comparing extreme quartiles of full-length RBP4 levels was 3.56 (95% confidence interval, 1.21-10.51; Ptrend=0.003), whereas this association was 0.77 (95% confidence interval, 0.38-1.56; Ptrend=0.44) in the follow-up period of 9 to 16 years. Results were similar for total RBP4 levels (summed levels of all RBP4 isoforms). Levels of the primary truncated isoform, RBP4-L, were not associated with CHD risk in any follow-up period; the odds ratios for extreme quartiles were 1.29 (95% confidence interval, 0.50-3.32) and 1.20 (95% confidence interval, 0.64-2.26) in the first and second 8 years of follow-up, respectively. CONCLUSIONS: In this cohort of women, higher circulating full-length and total RBP4 levels were associated with increased risk of CHD in a time-dependent fashion. Additional data are warranted to confirm the present findings.
BACKGROUND:Retinol-binding protein 4 (RBP4) may play an important role in the origin of insulin resistance and metabolic syndrome. Few prospective data are available on the relationship between RBP4 and coronary heart disease (CHD). Furthermore, previous studies did not distinguish among full-length and truncated forms of RBP4 that might have various biological activities. METHODS AND RESULTS: We measured plasma levels of full-length and several C-terminally truncated subfractions of RBP4 among 468 women who developed CHD and 472 matched controls in the Nurses' Health Study cohort during 16 years of follow-up (1990-2006). We observed a temporal variation in the association of full-length RBP4 levels with CHD risk (P=0.04 for testing proportional hazard assumption). In the first 8 years of follow-up, after multivariate adjustment for covariates, the odds ratio of CHD risk comparing extreme quartiles of full-length RBP4 levels was 3.56 (95% confidence interval, 1.21-10.51; Ptrend=0.003), whereas this association was 0.77 (95% confidence interval, 0.38-1.56; Ptrend=0.44) in the follow-up period of 9 to 16 years. Results were similar for total RBP4 levels (summed levels of all RBP4 isoforms). Levels of the primary truncated isoform, RBP4-L, were not associated with CHD risk in any follow-up period; the odds ratios for extreme quartiles were 1.29 (95% confidence interval, 0.50-3.32) and 1.20 (95% confidence interval, 0.64-2.26) in the first and second 8 years of follow-up, respectively. CONCLUSIONS: In this cohort of women, higher circulating full-length and total RBP4 levels were associated with increased risk of CHD in a time-dependent fashion. Additional data are warranted to confirm the present findings.
Entities:
Keywords:
RBP4 protein, human; epidemiology; heart diseases; myocardial infarction; women
Authors: Qin Yang; Iratxe Eskurza; Urban A Kiernan; David A Phillips; Matthias Blüher; Timothy E Graham; Barbara B Kahn Journal: Endocrinology Date: 2012-01-17 Impact factor: 4.736
Authors: Thomas Bobbert; Jens Raila; Franziska Schwarz; Knut Mai; Andrea Henze; Andreas F H Pfeiffer; Florian J Schweigert; Joachim Spranger Journal: Atherosclerosis Date: 2010-08-19 Impact factor: 5.162
Authors: Erik Ingelsson; Johan Sundström; Håkan Melhus; Karl Michaëlsson; Christian Berne; Ramachandran S Vasan; Ulf Risérus; Rune Blomhoff; Lars Lind; Johan Arnlöv Journal: Atherosclerosis Date: 2009-03-11 Impact factor: 5.162
Authors: Christa Meisinger; Ina M Rückert; Wolfgang Rathmann; Angela Döring; Barbara Thorand; Cornelia Huth; Bernd Kowall; Wolfgang Koenig Journal: Diabetes Care Date: 2011-05-26 Impact factor: 19.112
Authors: Jaume Amengual; Ning Zhang; Mary Kemerer; Tadao Maeda; Krzysztof Palczewski; Johannes Von Lintig Journal: Hum Mol Genet Date: 2014-05-22 Impact factor: 6.150
Authors: Gang Liu; Ming Ding; Stephanie E Chiuve; Eric B Rimm; Paul W Franks; James B Meigs; Frank B Hu; Qi Sun Journal: Arterioscler Thromb Vasc Biol Date: 2016-09-08 Impact factor: 8.311
Authors: Pedro M Moraes-Vieira; Mark M Yore; Peter M Dwyer; Ismail Syed; Pratik Aryal; Barbara B Kahn Journal: Cell Metab Date: 2014-03-04 Impact factor: 27.287
Authors: Pedro M Moraes-Vieira; Mark M Yore; Alexandra Sontheimer-Phelps; Angela Castoldi; Julie Norseen; Pratik Aryal; Kotryna Simonyté Sjödin; Barbara B Kahn Journal: Proc Natl Acad Sci U S A Date: 2020-11-19 Impact factor: 11.205
Authors: Laura Zemany; Bettina J Kraus; Julie Norseen; Tsugumichi Saito; Odile D Peroni; Randy L Johnson; Barbara B Kahn Journal: Mol Cell Biol Date: 2014-01-13 Impact factor: 4.272